Drug intelligence / Profile preview

Resverasin

Development stage
Unknown
Lead developer
NutriMed Group
Modality
Small Molecules
Administration
Oral
01

Overview

Resverasin is a multi-ingredient dietary supplement developed and marketed by NutriMed Group, a pharmaceutical company based in Ukraine. The product is designed to support cardiovascular health and provide systemic antioxidant protection. Its formulation includes resveratrol, red wine extract, and grape seed extract. Resveratrol, the primary active component, is a natural polyphenol that acts as a potent antioxidant and a positive allosteric modulator of NAD-dependent protein deacetylase sirtuin-1 (SIRT1). Activation of SIRT1 is associated with improved metabolic function, cellular longevity, and vascular protection. The additional extracts from red wine and grape seeds provide a spectrum of polyphenols and oligomeric proanthocyanidins that enhance endothelial function, inhibit lipid peroxidation, and support healthy blood pressure. Resverasin is typically indicated for individuals seeking to mitigate age-related cardiovascular risks and oxidative stress.

Brand names
Resverasin
Other names
Ресверазин
02

Targets

SIRT (Sirtuin family)SIRT5 (NAD-dependent protein deacylase sirtuin-5, mitochondrial)

Beyond the preview

Go deeper on Resverasin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resverasin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call